What is TiumBio?
TiumBio is a South Korea-based biopharmaceutical firm focused on the discovery and development of novel small molecule and biologic medicines. The company's pipeline targets critical therapeutic areas including immuno-oncology, fibrosis, endometriosis/uterine fibroids, and hemophilia. Founded and guided by a team of scientists, TiumBio is dedicated to addressing significant unmet medical needs for patients suffering from challenging diseases.
How much funding has TiumBio raised?
TiumBio has raised a total of $29.6M across 1 funding round:
Share Placement
$29.6M
Share Placement (2023): $29.6M, investors not publicly disclosed
What's next for TiumBio?
The recent major strategic investment signifies a pivotal moment for TiumBio, likely enabling the acceleration of its clinical and pre-clinical drug candidate development. This capital infusion is expected to fuel further research, expand its therapeutic programs, and potentially support the progression of its innovative treatments through later-stage trials, positioning the company for substantial growth and market impact.
See full TiumBio company page
